A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Public ClinicalTrials.gov record NCT05094336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.
Study identification
- NCT ID
- NCT05094336
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 329 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2022 (Actual)
- Primary completion
- Nov 30, 2026 (Estimated)
- Completion
- Nov 30, 2026 (Estimated)
- Last update posted
- May 28, 2026
2022 – 2026
United States locations
- U.S. sites
- 30
- U.S. states
- 14
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| California Research Institute | Glendale | California | 91204 | — |
| Fomat Medical Research | Oxnard | California | 93030 | — |
| University of California at SF | San Francisco | California | 94158 | — |
| D and H Cancer Research Center | Margate | Florida | 33063 | — |
| Boca Raton Clinical Research Medical Center Inc | Tamarac | Florida | 33321 | — |
| Goshen Health Systems | Goshen | Indiana | 46526 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Community Health Network MD Anderson Cancer Center - North | Indianapolis | Indiana | 46250 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| American Oncology Partners, PA | Bethesda | Maryland | 20817 | — |
| Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion) | Detroit | Michigan | 48202 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 32224 | — |
| Northwell Health Monter Cancer Center | Lake Success | New York | 11042 | — |
| New York University Grossman School of Medicine and New York University Langone Hospitals | New York | New York | 10016 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19106 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sanford Oncology Clinic and Pharmacy | Sioux Falls | South Dakota | 54104 | — |
| Sarah Cannon Research Institute | Dallas | Texas | 75230 | — |
| Center for Oncology and Blood Disorders | Houston | Texas | 77030 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Lumi Research | Kingwood | Texas | 77339 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05094336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05094336 live on ClinicalTrials.gov.